
News|Articles|February 1, 2008
FDA Pipeline Preview, February 2008
FDA-related information through February 2008 on Fluvoxamine extended-release capsules, dalbavancin, bazedoxifene, HPV vaccine (Cervarix), valrubicin, motexafin gadolinium, COL-003, CDX-110, sugammadex, mecaserim rinfabate, A-001, beclomethasone, clobazam, fludarabine tablets, JZP-8, and AST-120
Advertisement
Approvable designations
Complete response letter
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
WHO Global Report on Antimicrobial Resistance Sheds Light on Growing Threat
4
Sponsored: The Teva Biosimilars Trend Report
5